Milvexian (BMS-986177) is a potent antithrombotic compound that inhibits human and rabbit factor XIa (FXIa) directly and reversibly. It is orally-bioavailable and exhibits a K i of 0.11 nM and 0.38 nM against human and rabbit FXIa, respectively.
Defibrotide sodium is a complex blend of single-stranded polydeoxyribonucleotides, exhibiting liver protective, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. It is utilized in research related to sinusoidal obstruction syndrome (SOS) veno-occlusive disease (VOD) [1].